Table 1.
Effect of Treatment on Hematology and Biochemistry
| Days Post Infection | 5 | |||||
|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | ||
| Hematocrit (%) | ||||||
| Uninfected | 0.41 ± 0.03 | 0.41 ± 0.02 | 0.40 ± 0.05 | ND | ND | ND |
| MHV‐3 PBS | 0.41 ± 0.03 | 0.43 ± 0.03 | 0.42 ± 0.01 | — | — | — |
| MHV‐3 Ribavirin | 0.42 ± 0.03 | 0.36 ± 0.04 | 0.33 ± 0.01 | 0.31 ± 0.02 | 0.30 ± 0.01 | 0.31 ± .01 |
| MHV‐3 HRC 203 | 0.41 ± 0.03 | 0.40 ± 0.01 | 0.39 ± 0.02 | 0.41 ± 0.02 | 0.40 ± 0.02 | 0.42 ± .02 |
| Hemoglobin (g/L) | ||||||
| Uninfected | 139 ± 12 | 140 ± 11 | 139 ± 11 | ND | ND | ND |
| MHV‐3 PBS | 139 ± 11 | 139 ± 12 | 143 ± 7 | — | — | — |
| MHV‐3 Ribavirin | 139 ± 11 | 122 ± 11* | 119 ± 4* | 112 ± 3* | 111 ± 4* | 114 ± 2* |
| MHV‐3 HRC 203 | 140 ± 11 | 136 ± 4 | 136 ± 5 | 136 ± 4 | 134 ± 5 | 135 ± 2 |
| WBC (X10 9/L) | ||||||
| Uninfected | 8.3 | 8.4 | ND | ND | ND | ND |
| MHV‐3 PBS | 8.7 | 8.8 | 8.6 | — | — | — |
| MHV‐3 Ribavirin | 9.0 | 8.6 | 9.1 | 9.0 | 8.9 | 8.6 |
| MHV‐3 HRC 203 | 8.4 | 8.7 | 9.1 | 9.1 | 9.1 | 9.0 |
| Sodium (mmol/L) | ||||||
| Uninfected | 149 ± 1.2 | 148 ± 1.0 | 149 ± 1.2 | 147 ± 2.0 | ND | ND |
| MHV‐3 PBS | 145 ± 1.0 | 146 ± 1.7 | 147 ± 2.0 | 145 ± 1.3 | — | — |
| MHV‐3 Ribavirin | 148 ± 1.2 | 151 ± 1.4 | 147 ± 1.3 | 151 ± 1.3 | 148 ± 1.4 | 152 ± 1.4 |
| MHV‐3 HRC 203 | 148 ± 1.4 | 152 ± 1.1 | 148 ± 1.0 | 149 ± 1.3 | 142 ± 2.0 | 143 ± 1.4 |
| Bicarbonate (mmol/L) | ||||||
| Uninfected | 19.7 ± 2.3 | 20.1 ± 2.0 | 19.4 ± 2.0 | ND | ND | ND |
| MHV‐3 PBS | 19.1 ± 2.1 | 18.0 ± 1.4 | 17.7 ± 2.5 | 17.0 ± 2.1 | — | — |
| MHV‐3 Ribavirin | 18.9 ± 2.0 | 22.0 ± 2.0 | 18.0 ± 2.1 | 17.0 ± 1.1 | 21.0 ± 2.0 | 19 ± 2.2 |
| MHV‐3 HRC 203 | 20.0 ± 2.0 | 25.0 ± 2.2 | 18.0 ± 2.1 | 24.0 ± 2.1 | 21.0 ± 2.0 | 21 ± 1.8 |
| BUN (mmol/L) | ||||||
| Uninfected | 8.0 | 9.5 | ND | ND | ND | ND |
| MHV‐3 PBS | 8.0 | 11.2 | 19.2 | 14.3 | — | — |
| MHV‐3 Ribavirin | 9.0 | 11.0 | 9.5 | 8.0 | 11.5 | 11.2 |
| MHV‐3 HRC 203 | 9.0 | 10.5 | 9.5 | 6.0 | 7.0 | 6.0 |
| ALT (IU/L) | ||||||
| Uninfected | 30 ± 5 | 29 ± 6 | 31 ± 5 | ND | ND | ND |
| MHV‐3 PBS | 31 ± 7 | 65 ± 35 | 130 ± 110 | 7986 ± 325 | — | — |
| MHV‐3 Ribavirin | 35 ± 5 | 45 ± 7 | 70 ± 10 | 205 ± 10 | 878 ± 238 | 964 ± 128 |
| MHV‐3 HRC 203 | 40 ± 6 | 65 ± 5 | 45 ± 10 | 310 ± 20 | 587 ± 124 | 848 ± 212 |
NOTE. Data represents mean ± SD of 3 experiments.
Abbreviation: ND, not done; —, died before analysis.
*
P < .01 when MHV‐3+HRC 203–treated group was compared with MHV‐3+ribavirin‐treated group.